How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
- 17 December 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Quality of Life Research
- Vol. 29 (6), 1419-1431
- https://doi.org/10.1007/s11136-019-02392-6
Abstract
Purpose Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer due in part to changing treatment patterns. It is important to understand how changing treatment patterns affect patients’ lives beyond extending survival. Research suggests that direct patient report is the best way to capture information on how patients feel and function in response to their disease and its treatment. Therefore, the purpose of this review is to summarize evidence of patients’ experience collected through patient-reported outcomes (PRO) in RRMM patients, and to explore PRO reporting quality. Methods We conducted a systematic search to identify manuscripts reporting PROs in RRMM and summarized available evidence. We assessed PRO reporting quality using the Consolidated Standards of Reporting Trials (CONSORT) PRO Extension checklist. Results Our search resulted in 30 manuscripts. Thirteen unique PRO measures were used to assess 18 distinct PRO domains. Pain, fatigue, and emotional function were commonly assessed domains though reporting formats limited our ability to understand prevalence and severity of PRO challenges in RRMM. Evaluation of PRO reporting quality revealed significant reporting deficiencies. Several reporting criteria were included in less than 25% of manuscripts. Conclusions Existing evidence provides a limited window for understanding the patient experience of RRMM and is further limited by suboptimal reporting quality. Observational studies are needed to describe prevalence, severity and patterns of PROs in RRMM overtime. Future studies that incorporate PROs would benefit from following existing guidelines to ensure that study evidence and conclusions can be fully assessed by readers, clinicians and policy makers.Keywords
This publication has 72 references indexed in Scilit:
- Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult OncologyJournal of Clinical Oncology, 2012
- Combination of Cyclophosphamide, Etoposide, Carboplatin and Dexamethasone as a Salvage Regimen for Refractory Multiple Myeloma Patients: A Comparison with a Historical Control GroupHematology Reports, 2012
- Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyEuropean Journal of Haematology, 2012
- The Missing Voice of Patients in Drug-Safety ReportingThe New England Journal of Medicine, 2010
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical OutcomesJNCI Journal of the National Cancer Institute, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004